TY - JOUR T1 - Dietary Recommendations for Familial Hypercholesterolaemia: an Evidence-Free Zone JF - BMJ Evidence-Based Medicine JO - BMJ EBM DO - 10.1136/bmjebm-2020-111412 SP - bmjebm-2020-111412 AU - David M Diamond AU - Abdullah A Alabdulgader AU - Michel de Lorgeril AU - Zoe Harcombe AU - Malcolm Kendrick AU - Aseem Malhotra AU - Blair O'Neill AU - Uffe Ravnskov AU - Sherif Sultan AU - Jeff S Volek Y1 - 2020/07/05 UR - http://ebm.bmj.com/content/early/2020/07/05/bmjebm-2020-111412.abstract N2 - We have evaluated dietary recommendations for people diagnosed with familial hypercholesterolaemia (FH), a genetic condition in which increased low-density lipoprotein cholesterol (LDL-C) is associated with an increased risk for coronary heart disease (CHD). Recommendations for FH individuals have emphasised a low saturated fat, low cholesterol diet to reduce their LDL-C levels. The basis of this recommendation is the ‘diet-heart hypothesis’, which postulates that consumption of food rich in saturated fat increases serum cholesterol levels, which increases risk of CHD. We have challenged the rationale for FH dietary recommendations based on the absence of support for the diet-heart hypothesis, and the lack of evidence that a low saturated fat, low cholesterol diet reduces coronary events in FH individuals. As an alternative approach, we have summarised research which has shown that the subset of FH individuals that develop CHD exhibit risk factors associated with an insulin-resistant phenotype (elevated triglycerides, blood glucose, haemoglobin A1c (HbA1c), obesity, hyperinsulinaemia, high‐sensitivity C reactive protein, hypertension) or increased susceptibility to develop coagulopathy. The insulin-resistant phenotype, also referred to as the metabolic syndrome, manifests as carbohydrate intolerance, which is most effectively managed by a low carbohydrate diet (LCD). Therefore, we propose that FH individuals with signs of insulin resistance should be made aware of the benefits of an LCD. Our assessment of the literature provides the rationale for clinical trials to be conducted to determine if an LCD would prove to be effective in reducing the incidence of coronary events in FH individuals which exhibit an insulin-resistant phenotype or hypercoagulation risk. ER -